IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer
Lv, Chunxin1; Liu, Xiuju2; Zheng, Qiwen3; Chen, Hanxiao4; Yang, Xue4; Zhong, Jia4; Wang, Yuyan4; Duan, Jianchun5,6; Wang, Zhijie5,6; Bai, Hua5,6; Wu, Meina4; Zhao, Jun4; Wang, Jie5,6; Wang, Ziping4; An, Tongtong4; Zhuo, Minglei4
通讯作者An, Tongtong(4) ; Zhuo, Minglei(4)
关键词Second-line chemotherapy small cell lung cancer topoisomerase-1 topotecan
刊名THORACIC CANCER
2018-09-01
DOI10.1111/1759-7714.12819
9期:9页:1166-1173
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Respiratory System
研究领域[WOS]Oncology ; Respiratory System
关键词[WOS]PHASE-III TRIAL ; CAMPTOTHECIN ; SENSITIVITY ; INHIBITORS ; CRITERIA ; PROGRESS ; TUMORS ; GENE
英文摘要

BackgroundWe evaluated topoisomerase I (TOPO1) expression in patients with small cell lung cancer (SCLC) and identified predictive factors for the efficacy of second-line topotecan chemotherapy.

MethodsWe retrospectively evaluated the records of SCLC patients treated in our department from January 2007 to December 2016 who received second-line topotecan chemotherapy. Patients with archived tumor samples were enrolled. TOPO1 expression levels were evaluated by immunohistochemistry, and the relationships between TOPO1 expression, clinical factors, chemotherapy efficacy, and survival were analyzed.

ResultsOf the 78 patients enrolled, 67 showed TOPO1 expression (85.9%). Patients were divided into strong (n=43) or weak (n=35) expression groups based on staining intensity. Disease control rates for topotecan were 39.5% and 14.3% in the strong and weak groups, respectively (P= 0.014). Second-line median progression-free survival was 2.2 and 2.0 months (P=0.057), and median overall survival was 8.1 and 6.0 months (P=0.199) in the strong and weak positive groups, respectively. Patients were also divided into sensitive (n=47) and refractory (n=31) disease groups according to the duration from the onset of first-line therapy to relapse. Median second-line progression-free survival was 2.2 and 1.8 months in the sensitive and refractory relapse groups, respectively (P= 0.005).

ConclusionsTOPO1 expression was prevalent in SCLC patients. Strong expression was associated with an elevated disease control rate after second-line topotecan chemotherapy. Patients with sensitive disease that relapsed after first-line chemotherapy had better survival than refractory patients who received second-line topotecan chemotherapy.

语种英语
WOS记录号WOS:000443415700010
通讯作者邮箱antt508@sina.com ; minglei1978@163.com
第一作者单位Fudan Univ, Minhang Hosp, Dept Geriatr, Shanghai, Peoples R China
通讯作者单位Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Dept Thorac Med Oncol 1, Fucheng Rd 52, Beijing 100142, Peoples R China
ISSN1759-7706
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/142908
专题北京大学公共卫生学院
北京大学口腔医学院_急诊科
北京大学临床肿瘤学院_胸部肿瘤内科
作者单位1.Fudan Univ, Minhang Hosp, Dept Geriatr, Shanghai, Peoples R China;
2.Shandong Canc Hosp & Inst, Dept Med Oncol, Jinan, Shandong, Peoples R China;
3.Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing, Peoples R China;
4.Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Dept Thorac Med Oncol 1, Fucheng Rd 52, Beijing 100142, Peoples R China;
5.Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Beijing, Peoples R China;
6.Peking Union Med Coll, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Lv, Chunxin,Liu, Xiuju,Zheng, Qiwen,et al. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer[J]. THORACIC CANCER,2018,9(9):1166-1173.
APA Lv, Chunxin.,Liu, Xiuju.,Zheng, Qiwen.,Chen, Hanxiao.,Yang, Xue.,...&Zhuo, Minglei.(2018).Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.THORACIC CANCER,9(9),1166-1173.
MLA Lv, Chunxin,et al."Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer".THORACIC CANCER 9.9(2018):1166-1173.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lv, Chunxin]的文章
[Liu, Xiuju]的文章
[Zheng, Qiwen]的文章
百度学术
百度学术中相似的文章
[Lv, Chunxin]的文章
[Liu, Xiuju]的文章
[Zheng, Qiwen]的文章
必应学术
必应学术中相似的文章
[Lv, Chunxin]的文章
[Liu, Xiuju]的文章
[Zheng, Qiwen]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。